Pharmalittle: Bayer offered funding to influence foreign press group; a key Sanofi exec leaves as changes loom

first_img GET STARTED Pharmalittle: Bayer offered funding to influence foreign press group; a key Sanofi exec leaves as changes loom By Ed Silverman Nov. 22, 2019 Reprints STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. [email protected] And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is once again rather modest. We hope to hang with one or more short people, catch up on our reading, and take a constitutional walk or two. And what about you? There is a holiday looming on this side of the pond, so this may be an opportunity to plan a menu or an invitation list, the hazards of family gatherings notwithstanding. Alternatively, you could ignore the hullabaloo and plot an escape to somewhere faraway. Or you can simply take stock and enjoy the respite. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.Bayer (BAYRY) communications executives discussed plans to give the drug maker influence within a prestigious American not-for-profit dedicated to media freedoms that would protect and promote the company’s business interests in exchange for generous funding, The Guardian reveals. Emails indicated the company sought a voice in several initiatives of the Foreign Press Association and its related foundation with a goal of “adding value to Bayer and the FPA.” And Bayer was to be “actively informed and involved in the supervision of these planned initiatives.” What’s included? Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Ed Silverman Log In | Learn More center_img What is it? Pharmalot @Pharmalot Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Alex Hogan/STAT Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED About the Author Reprints Tags pharmalittleSTAT+last_img

Leave a Reply

Your email address will not be published. Required fields are marked *